Lyka Labs Ltd

AGM Details

• AGM date and mode: 10 August 2026, VC/OAVM.
• Start time 12:30 PM; end time 01:05 PM.
• Record date: 03 August 2026; on-record shareholders: 29,814.
• Total resolutions passed: 5.

Resolutions and outcomes

• Resolution 1(a): Adoption of Audited Financial Statements; ordinary; passed.
• Resolution 1(b): Adoption of Audited Consolidated Financial Statements; ordinary; passed.
• Resolution 2: Re-appointment of Shashil Philip Mendosa (DIN 09667654); ordinary; passed.
• Resolution 3: Ratification of remuneration of Cost Auditor for FY 2025-26; ordinary; passed.
• Resolution 4: Ratification of remuneration of Cost Auditor for FY 2026-27; ordinary; passed.
• Resolution 5: Approval of Related Party Transactions for FY 2026-27 with IPCA Laboratories; ordinary; passed.

Voting observations

• All resolutions passed; majority in favour across the board.
• Interested directors and relatives abstained from RPT voting.

Q1 FY27 results and revision

• Revised press release for Q1 FY27 unaudited results; corrections to figures; submitted Aug 11, 2026.
• Standalone revenue from operations: 4,230.94 Lacs; up 45.01% YoY.
• Consolidated revenue from operations: 4,230.94 Lacs; up 28.11% YoY.
• Domestic revenue: 2,652.11 Lacs (Branded Formulation 737.67; Veterinary 587.35; P2P 1,327.09).
• Export revenue: 1,483.42 Lacs; up 68.03%.
• Standalone EBITDA margin: 11.84%; Consolidated EBITDA margin: 11.74%.
• Standalone net profit after tax: 210.03 Lacs; up 159.06%.
• Consolidated net profit after tax: 204.66 Lacs; up 105.44%.
• Other income: standalone 41.85 Lacs; down 45.89%.

AGM Details

• 47th AGM held on 10 August 2026 at 12:30 PM via VC/OAVM.
• 66 members attended; quorum satisfied.
• Results pending; combined voting results to be announced later.

Resolutions Put to Vote

• Adoption of Audited Financial Statements (including consolidated) for FY2025-26.
• Appointment of Director retiring by rotation.
• Ratification of Cost Auditor remuneration for FY2025-26.
• Ratification of Cost Auditor remuneration for FY2026-27.
• Approval of material related party transactions with IPCA Laboratories for 2026-27.

Voting Results

• Voting results pending; combined results to be announced within timeline.

Directors & Auditors

• No director changes announced at the AGM.
• Statutory Auditors attended; Cost Auditor remuneration ratified for FY2025-26 and FY2026-27.

Q1 FY27 results overview

• Unaudited Q1 FY27 results for Lyka Labs: standalone and consolidated financials for quarter ended 30 June 2026.
• Standalone Net Total Income rose 42.67% to Rs 4272.79 Lacs.
• Consolidated Net Total Income rose 26.95% to Rs 4272.79 Lacs.
• Domestic Revenue up 15.91% to Rs 2652.11 Lacs.
• Export Revenue up 68.03% to Rs 1483.42 Lacs.
• Standalone EBITDA margin 11.84% vs 14.16% in Q1 FY26.
• Consolidated EBITDA margin 11.74% vs 13.07% in Q1 FY26.
• Standalone Net Profit up 159.04% to Rs 210.01 Lacs.
• Consolidated Net Profit up 105.44% to Rs 204.66 Lacs.
• Board approved Q1 FY27 unaudited results at the August 10, 2026 meeting.

Financial results approved

• Unaudited standalone and consolidated Q1 2026 results approved by Board; Limited Review Report enclosed.

Divestment of Lyka BDR International Limited

• Board approved divestment of 100% equity in Lyka BDR International Limited; Audit Committee to implement.

NCLT merger sanction and restatement

• NCLT sanctioned merger of Lyka Export Limited with Lyka Labs Limited; restatement per IND AS 103.

Auditors' conclusions

• Statutory auditors express unqualified conclusion on both standalone and consolidated unaudited results.

Subsidiary disclosures

• Annexure notes Lyka BDR turnover 8% of consolidated income; net worth negative.

AGM Details & Voting

• AGM date/time: 10 August 2026 at 12:30 p.m., via VC/OAVM.
• Remote e-voting window: 6 August 2026, 9:00 a.m. to 9 August 2026, 5:00 p.m.
• Cut-off date for voting rights: 3 August 2026.
• Notice and Annual Report sent electronically; physical copies dispensed per MCA/SEBI rules.
• Annual Report also available on the company's website.
• Shareholders may request electronic copy by emailing the Company Secretary.

Key updates

• 47th AGM on 10 August 2026 at 12:30 PM IST via VC/OAVM.
• Annual Report for FY 2025-26 available on Lyka Labs website.
• Letter sent to shareholders without registered emails with access link; cut-off for email registration: 10 July 2026.
• Reminder to update KYC per SEBI circular; required fields include PAN, address, mobile, bank details, and nomination.
• SEBI mandates electronic payments to physical folios lacking updated details from 1 April 2024.
• Queries via investor.helpdesk@in.mpms.mufg.com; service requests via MUFG portal.

Standalone financials

• Standalone revenue Rs 12,487.97 L, down from Rs 13,745.74 L.
• Standalone PBT Rs -3,323.53 L; PAT Rs -3,228.84 L.
• Net tax expense Rs -177.48 L; EPS Rs -9.05.
• One-time impairment of investment/loan in Lyka Exports Ltd: Rs 2,301.44 L.
• Operating cash from standalone activities Rs 524.28 L; year-end cash Rs 118.61 L.

Consolidated results

• Consolidated revenue Rs 13,194.24 L; PAT Rs -1,057.96 L.
• Consolidated EPS Rs -2.81; impairment of Lyka BDR International Ltd Rs 2,301.44 L.
• Comparatives restated due to merger under common control with Lyka Exports Ltd.

Merger & corporate actions

• NCLT sanctioned merger of Lyka Exports Ltd with Lyka Labs Ltd on 16 Mar 2026.
• Appointed date for merger: 1 Apr 2022; pooling of interests method.
• Share swap: 4,62,711 equity shares to Lyka Exports shareholders; issuance pending.
• Comparatives restated to reflect merger effects.

Capital structure & liquidity

• Total borrowings Rs 4,835.59 L; long-term Rs 2,298.93 L; short-term Rs 2,536.66 L.
• Debt-to-equity (standalone) 0.58x; current ratio 1.13x; interest coverage negative.
• Consolidated net cash from operations Rs 524.28 L; net cash increase Rs 1.51 L.

Strategic developments & outlook

• Lyophilisation capacity to expand by 50%; completion targeted in 2026.
• New FertiNova division for IVF and women’s health products.
• 24 new product registrations filed; 2 approvals; 19 registrations expected next year.
• Pregabalin Gel launched in India in 2024; focus on domestic and international markets.

Related party transactions

• IPCA Laboratories Limited is a promoter; Lyka holds 40.98% stake.
• Material related party transactions with IPCA for FY2026-27 up to Rs 75 crore.
• Audit Committee reviews RPTs; shareholders’ approval sought for material RPT.

Dividends & CSR

• Dividend not recommended for 2025-26.
• CSR spent Rs 7.20 L; requirement Rs 4.35 L; excess Rs 2.85 L carry-forward.
• CSR committee ongoing; JUJVA Vibhag Kelavani Mandal project noted.

Governance & controls

• Statutory auditors: D. Kothary & Co; Secretarial: Kaushal Doshi & Associates; Cost auditors: Tibrewala & Co.
• Independent Directors: Archana Yadav appointed 26 May 2025; Dhara Shah ceased 3 Aug 2025.
• Board meetings: 6; Audit Committee: 5; Nomination & Remuneration: 4; CSR Committee: 2.
• CEO/CFO certifications; internal controls deemed adequate; going concern confirmed.

Regulatory & legal

• NCLT scheme sanctioned; various regulatory approvals noted.
• Contingent liabilities disclosed; no material provisions required as at year-end.